Bioventus Inc. cash flow statement

In fiscal 2025, Bioventus Inc.'s operations generated $74.7m of cash; it spent $2.6m on capital projects, leaving free cash flow of $72.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bioventus Inc.: cash flow statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash from operations	41	72	23	−14	15	39	75	87
Depreciation and amortisation	30	29	35	55	57	50	47	25
Stock-based pay	0	0	20	18	3	13	13	16
Capital spending	2	17	14	1	7	1	3	2
Free cash flow	38	55	9	−15	8	38	72	85
Free cash flow after stock pay	38	55	−10	−33	5	25	59	69
Shares issued	0	0	2	6	1	2	2	3

US$ millions unless shown otherwise. Fiscal quarters.

Bioventus Inc.: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Cash from operations	19	−19	26	30	38	9	20	21
Depreciation and amortisation	12	12	1	1	12	11	1	1
Stock-based pay	2	2	3	3	3	3	5	5
Capital spending	1	1	1	0	1	1	1	0
Free cash flow	19	−20	25	30	37	8	19	20
Free cash flow after stock pay	17	−23	22	26	34	5	14	16
Shares issued	1	0	1	0	1	0	1	1

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ATRC vs BVS BVS vs TMDX BVS vs GKOS AORT vs BVS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bioventus Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioventus Inc.